NYSE American - Delayed Quote USD

Palatin Technologies, Inc. (PTN)

1.8200 +0.1000 (+5.81%)
At close: April 26 at 4:00 PM EDT
1.7600 -0.06 (-3.30%)
After hours: April 26 at 6:14 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Carl Spana Ph.D. Co-Founder, President, CEO & Director 979k -- 1962
Mr. Stephen T. Wills CPA, MST CFO, COO, Executive VP, Treasurer & Secretary 910.55k -- 1957
Burns McClellan Vice President of Investor Relations -- -- --
Mr. Stephen A. Slusher Esq. Chief Legal Officer -- -- --
Dr. Michael B. Raizman M.D. Chief Medical Officer -- -- --
Mr. James E. Hattersley Senior Vice President of Business Development -- -- 1960
Mr. John Dodd Ph.D. Senior Vice President of Preclinical Development -- -- --
Mr. Robert Jordan Senior Vice President of Program Operations -- -- --

Palatin Technologies, Inc.

Cedar Brook Corporate Center
4-B Cedar Brook Drive
Cranbury, NJ 08512
United States
609 495 2200 https://palatin.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
34

Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Corporate Governance

Palatin Technologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 14, 2024 - May 20, 2024
Palatin Technologies, Inc. Earnings Call

Related Tickers

EYEN Eyenovia, Inc.
0.6282
-11.68%
 
DOMH Dominari Holdings Inc.
2.7000
-0.37%
 
BRTX BioRestorative Therapies, Inc.
1.2500
+1.63%
 
NRXP NRx Pharmaceuticals, Inc.
3.5400
+12.74%
 
VNDA Vanda Pharmaceuticals Inc.
4.6200
+3.12%
 
ZVSA ZyVersa Therapeutics, Inc.
4.9900
-16.83%
 
LPCN Lipocine Inc.
4.7977
+6.14%
 
CDXS Codexis, Inc.
2.6600
+0.38%
 
SILO Silo Pharma, Inc.
1.8500
-2.63%
 
MBIO Mustang Bio, Inc.
0.3161
-11.58%